Tudóstér: Mezei Zoltán András publikációi

Baráth, S., Singh, P., Hevessy, Z., Ujfalusi, A., Mezei, Z., Balogh, M., Széles, M., Kappelmayer, J.: Enhancing HLA-B27 antigen detection: Leveraging machine learning algorithms for flow cytometric analysis.
Cytom. Part B-Clin. Cytom. [Epub ahead of print]2024.

Pethő, Á., Nagy, Z., Mezei, Z., Takács, I., Demeter, J.: Béta-thalassaemia, B12-vitamin-hiány és társuló komplementmediált hemolízis.
Orv. hetil. 164 (24), 954-960, 2023.

Singh, P., Széles, M., Mezei, Z., Baráth, S., Hevessy, Z.: Age-dependent frequency of unconventional T cells in a healthy adult Caucasian population: a combinational study of invariant natural killer T cells, [gamma][delta] T cells, and mucosa-associated invariant T cells.
GeroScience. 44 (4), 2047-2060, 2022.

Baráth, S., Mezei, Z., Széles, M., Hevessy, Z.: Combined use of different antibody clones improves the efficiency of human leukocyte antigen B27 detection by flow cytometry.
Cytom. Part B-Clin. Cytom. 102 (3), 239-245, 2022.

Singh, P., Széles, M., Mezei, Z., Baráth, S., Hevessy, Z.: Gender-dependent frequency of unconventional T cells in a healthy adult Caucasian population: a combinational study of invariant NKT cells, [gamma] [delta] T cells, and mucosa-associated invariant T cells.
J. Leukoc. Biol. 112 (5), 1155-1165, 2022.

Bereczky, Z., Gindele, R., Fiatal, S., Speker, M., Miklós, T., Balogh, L., Mezei, Z., Szabó, Z., Ádány, R.: Age and Origin of the Founder Antithrombin Budapest 3 (p.Leu131Phe) Mutation; Its High Prevalence in the Roma Population and Its Association With Cardiovascular Diseases.
Front. Cardiovasc. Med. 7 1-15, 2021.

Koczok, K., Horváth, L., Korade, Z., Mezei, Z., P. Szabó, G., Porter, N., Kovács, E., Mirnics, K., Balogh, I.: Biochemical and Clinical Effects of Vitamin E Supplementation in Hungarian Smith-Lemli-Opitz Syndrome Patients.
Biomolecules. 11 (8), 1-11, 2021.

Szántó, K., Mezei, Z., Kata, D., Földesi, I., Nyári, T., Fábián, A., Rutka, M., Bor, R., Bálint, A., Milassin, Á., Szepes, Z., Nagy, F., Palatka, K., Farkas, K., Molnár, T.: Combination therapy with anti-TNFs and thiopurines does affect drug metabolite levels but it is not associated with body composition in inflammatory bowel disease patients: a cross-sectional study.
Gasztroenterol. Hepatol. Szle. 7 (4), 164-170, 2021.

Baráth, B., Kissné Bogáti, R., Miklós, T., Kállai, J., Mezei, Z., Bereczky, Z., Muszbek, L., Katona, É.: Effect of [alfa]2-plasmin inhibitor heterogeneity on the risk of venous thromboembolism.
Thromb. Res. 203 110-116, 2021.

Mezei, Z., Tornai, D., Földesi, R., Madar, L., Sümegi, A., Papp, M., Antal-Szalmás, P.: A DNA pool of FLT3-ITD positive DNA samples can be used efficiently for analytical evaluation of NGS-based FLT3-ITD quantitation: testing several different ITD sequences and rates, simultaneously.
J. Biotechnol. 303 25-29, 2019.

Szántó, K., Szíjártó, A., Kata, D., Földesi, I., Mezei, Z., Fábián, Á., Bálint, A., Bor, R., Farkas, K., Milassin, Á., Rutka, M., Szepes, Z., Nagy, F., Bubán, T., Lovas, S., Palatka, K., Molnár, T.: Blood thiopurine level, anti-TNF drug level and body composition parameters in inflammatory bowel diseases patients: a cross-sectional study in a Hungarian IBD centre.
J. Crohns Colitis. 13 (Supplement1), S456, 2019.

Katona, É., Kissné Bogáti, R., Miklós, T., Gindele, R., Speker, M., Fedoriska, V., Orosz, A., Mezei, Z., Bereczky, Z.: ALPHA-2 Plasmin Inhibitor Activity and Antigen Levels and p.Arg6Trp Polymorphism in Patients with Venous Thromboembolism.
Proceedings. 2 (9), 102-103, 2018.

Balogh, L., Katona, É., Mezei, Z., Kállai, J., Gindele, R., Édes, I., Muszbek, L., Papp, Z., Bereczky, Z.: Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.
Mol. Cell. Biochem. 448 (1-2), 199-209, 2018.

Székely, E., Czuriga-Kovács, K., Bereczky, Z., Katona, É., Mezei, Z., Nagy, A., Tóth, N., Berényi, E., Muszbek, L., Csiba, L., Bagoly, Z.: Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients.
Sci. Rep. 8 (1), 1-9, 2018.

Gindele, R., Colombo, R., Szabó, Z., Speker, M., Mezei, Z., Balogh, L., Katona, É., Bagoly, Z., Fiatal, S., Bereczky, Z.: Prevalence of Antithrombin Budapest 3 Mutation among Different Patients Groups; Investigation of the Age and Origin of Mutation Common in Hungary.
Proceedings. 2 (9), 76-77, 2018.

Kurdi, B., Mezei, Z., Kellner, Á., Egyed, M.: Thalassaemiás betegen észlelt anaemia perniciosa: a diagnózis nehézségei.
Orv. hetil. 159 (33), 1368-1371, 2018.

Katona, É., Kissné Bogáti, R., Miklós, T., Gindele, R., Speker, M., Fedoriska, V., Orosz, A., Mezei, Z., Bereczky, Z.: The Effect of Alpha-2 Plasmin Inhibitor Activity and Antigen Levels and p.Arg6Trp Polymorphism on the Risk of Venous Thromboembolism.
Res Pract Thromb Haemost. 2 324-324, 2018.

Mádi, A., Cuaranta-Monroy, I., Lénárt, K., Pap, A., Mezei, Z., Kristóf, E., Oláh, A., Vámosi, G., Bacsó, Z., Bai, P., Fésüs, L.: Browning deficiency and low mobilization of fatty acids in gonadal white adipose tissue leads to decreased cold-tolerance of transglutaminase 2 knock-out mice.
Biochim. Biophys. Acta. Mol. Cell Biol. Lipids. 1862 (12), 1575-1586, 2017.

Mezei, Z., Katona, É., Kállai, J., Bereczky, Z., Somodi, L., Molnár, É., Kovács, B., Miklós, T., Ajzner, É., Muszbek, L.: Factor XIII levels and factor XIII B subunit polymorphisms in patients with venous thromboembolism.
Thromb. Res. 158 93-97, 2017.

Mezei, Z., Katona, É., Kállai, J., Bereczky, Z., Molnár, É., Kovács, B., Ajzner, É., Bagoly, Z., Miklós, T., Muszbek, L.: Regulation of plasma factor XIII levels in healthy individuals; a major impact by subunit B intron K c.1952+144 C>G polymorphism.
Thromb. Res. 148 101-106, 2016.

Mezei, Z., Bereczky, Z., Katona, É., Gindele, R., Balogh, E., Fiatal, S., Balogh, L., Czuriga, I., Ádány, R., Édes, I., Muszbek, L.: Factor XIII B Subunit Polymorphisms and the Risk of Coronary Artery Disease.
Int. J. Mol. Sci. 16 (1), 1143-1159, 2015.

Shemirani, A., Antalfi, B., Pongrácz, E., Mezei, Z., Bereczky, Z., Csiki, Z.: Factor XIII-A subunit Val34Leu polymorphism in fatal atherothrombotic ischemic stroke.
Blood Coagul. Fibrinolysis. 25 (4), 364-368, 2014.

Antalfi, B., Pongrácz, E., Csiki, Z., Mezei, Z., Shemirani, A.: Factor XIII-A subunit Val34Leu polymorphism in fatal hemorrhagic stroke.
Int. J. Lab. Hematol. 35 (1), 88-91, 2013.

Bagoly, Z., Székely, E., Kovács, K., Mezei, Z., Katona, É., Kappelmayer, J., Csiba, L., Muszbek, L.: The effect of factor XIII and other regulators of fibrinolysis on the outcome of thrombolysis in ischemic stroke patients.
J. Thromb. Haemost. 11 (s2), 405-406, 2013.

Koncz, Z., Bagoly, Z., Haramura, G., Mezei, Z., Muszbek, L.: Thrombomodulin-dependent effect of factor VLeiden mutation on factor XIII activation.
Thromb. Res. 129 (4), 508-513, 2012.

Koncz, Z., Bagoly, Z., Haramura, G., Mezei, Z., Muszbek, L.: Thrombomodulin-dependent effect of factor V Leiden mutation on the cross-linking of alfa2-plasmin inhibitor to fibrin and its consequences on fibrinolysis.
Thromb. Res. 130 (3), 528-534, 2012.